Genmab A/S (NASDAQ:GMAB) Hits New 12-Month Low – Should You Sell?

Genmab A/S (NASDAQ:GMAB) hit a new 52-week low on Monday . The company traded as low as $18.87 and last traded at $18.99, with a volume of 103803 shares changing hands. The stock had previously closed at $19.00.

Analysts Set New Price Targets

Several equities analysts recently issued reports on GMAB shares. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Genmab A/S has a consensus rating of “Moderate Buy” and an average price target of $45.20.

Genmab A/S Trading Down 1.6 %

The stock has a market cap of $12.38 billion, a P/E ratio of 18.18, a PEG ratio of 0.54 and a beta of 0.96. The firm’s 50-day simple moving average is $20.84 and its 200 day simple moving average is $23.37.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Two Sigma Advisers LP lifted its stake in shares of Genmab A/S by 84.1% in the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after acquiring an additional 280,900 shares during the period. FMR LLC lifted its position in Genmab A/S by 13.5% in the third quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after purchasing an additional 33,076 shares during the period. Oppenheimer Asset Management Inc. boosted its stake in Genmab A/S by 6.5% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 232,243 shares of the company’s stock valued at $5,662,000 after purchasing an additional 14,165 shares in the last quarter. Natixis Advisors LLC increased its position in shares of Genmab A/S by 29.8% during the 3rd quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock valued at $5,036,000 after purchasing an additional 47,437 shares during the period. Finally, ABC Arbitrage SA bought a new stake in shares of Genmab A/S in the 4th quarter worth $3,692,000. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.